- AnaptysBio Inc ANABa clinical-stage biotechnology company focused on immunological therapeutics has sold its interest in future global net sales of Zejula (niraparib) to a wholly owned subsidiary of DRI Healthcare Trust for up to $45 million.
- GSK Plc GSK Zejula is indicated as monotherapy for the maintenance therapy of advanced ovarian cancer.
- AnaptysBio has received an upfront payment of US$35 million for the sale of its 1% royalty on Zejula’s worldwide net sales, which will be paid at an effective rate of 0.5% due to cuts related to third party royalty payments .
- Related: Raymond James initiates AnaptysBio with ~42% upside despite trial setback.
- The company is also eligible to receive an additional $10 million from DRI if Zejula is FDA approved for endometrial cancer.
- The drug is currently in a fully enrolled ongoing Phase 3 study, pending such approval on or before December 31, 2025.
- Earlier this month, AnaptysBio suffered a setback when it conducted the Phase 2 HARP trial of imsidolimab in moderate-to-severe hidradenitis suppurativa showed no efficacy over placebo.
- Price promotion: ANAB shares are up 0.58% to $25.83 on Monday’s latest check.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
